Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery TechnologyGlobeNewsWire • 04/08/24
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform DevelopmentGlobeNewsWire • 04/04/24
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 04/03/24
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 04/01/24
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsGlobeNewsWire • 03/26/24
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateGlobeNewsWire • 03/18/24
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600GlobeNewsWire • 02/26/24
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease SymposiumGlobeNewsWire • 02/08/24
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.GlobeNewsWire • 01/22/24
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery PlatformGlobeNewsWire • 01/02/24
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery PlatformGlobeNewsWire • 12/19/23
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional InvestorsGlobeNewsWire • 12/18/23
Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery PlatformGlobeNewsWire • 12/11/23
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative ColitisGlobeNewsWire • 11/30/23
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/13/23
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate UpdateGlobeNewsWire • 11/06/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biora Therapeutics, Inc. - BIORPRNewsWire • 11/03/23
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of DiabetesGlobeNewsWire • 10/05/23